中文版本

Opportunity

Nanoparticles, particularly lanthanide-doped upconverting nanoparticles (UCNPs), possess unique optical properties valuable for applications in biomedical imaging, sensing, and photonics. However, a significant barrier to their practical use, especially in biological environments, is their inherent hydrophobicity. As-synthesized UCNPs are typically capped with organic ligands like oleic acid, which are essential for controlling size and shape during synthesis but render the nanoparticles insoluble in aqueous solutions. This hydrophobicity prevents their dispersion in water, a fundamental requirement for most biological and medical applications. Existing methods to address this, such as direct ligand exchange, involve replacing the native hydrophobic ligands with hydrophilic ones. While conceptually simple, these methods suffer from several critical drawbacks. The exchange process often has slow kinetics, requires tedious optimization of conditions for different nanoparticle systems, and can lead to nanoparticle aggregation. Furthermore, the work-up procedures are cumbersome, and the resulting ligand attachment may be weak, compromising colloidal stability. This creates a pressing need for a robust, generalizable, and efficient surface modification technique that can reliably convert hydrophobic nanoparticles into stable, water-dispersible, and biocompatible platforms without compromising their core functionality or the integrity of the attached bioactive molecules.

Technology

The invention provides a novel two-step method for surface modification that fundamentally separates the ligand removal and ligand attachment processes. The core innovation lies in this decoupled approach, followed by a solvothermal treatment. First, the native hydrophobic ligands (e.g., oleate) are completely stripped from the nanoparticle surface using a mild acid treatment, such as hydrochloric acid, creating "ligand-free" nanoparticles. This initial cleansing step is performed independently. Second, in a separate and distinct step, the ligand-free nanoparticles are mixed with an excess of new, desired hydrophilic ligands. This mixture forms "preliminary modified nanoparticles" where the new ligands are only weakly adsorbed. The critical third phase is a solvothermal treatment, where the mixture, often in a solvent like diethylene glycol, is heated under controlled conditions (e.g., 160-200°C in an autoclave). This treatment converts the weakly adsorbed ligands into firmly bonded ones, permanently anchoring them to the nanoparticle surface. The method emphasizes pH adjustment (typically to pH 8) of the new ligand solution prior to mixing to optimize binding. By separating removal and attachment, the process eliminates competition between old and new ligands, ensures complete surface clearance for new ligand binding, and allows for a standardized protocol applicable to a wide variety of ligand and nanoparticle types. The solvothermal step ensures strong covalent or coordinative bonding, leading to exceptional stability.<

Advantages

• Provides a robust and generalizable protocol applicable to various nanoparticles (lanthanide-doped, metal, metal oxide, semiconductor) and a wide range of ligands.
• The separate removal and attachment steps ensure complete elimination of native ligands and more efficient, reliable coating with new ligands compared to direct exchange methods.
• Solvothermal treatment ensures firm, stable bonding of new ligands to the nanoparticle surface, preventing desorption.
• Results in modified nanoparticles with excellent water dispersibility and high colloidal stability.
• Offers good biocompatibility, as demonstrated by cell viability assays.
• Allows for the direct attachment of functional biomolecules (e.g., biotin, cysteine, glycine) while preserving their bioactivity, as the controlled solvothermal conditions minimize degradation.
• Simplifies the process compared to direct exchange by reducing the need for highly optimized, system-specific conditions and complex equipment setups.
• Minimizes nanoparticle aggregation during the modification process.

Applications

• Biomedical Imaging: Creating biocompatible probes for upconversion luminescence (UCL) bioimaging, where near-infrared excitation offers deep tissue penetration and minimal autofluorescence.
• Drug Delivery: Serving as functionalized nanocarriers where surface ligands can be used for targeting specific cells or tissues.
• Biosensing: Acting as platforms for biosensors where surface-attached biomolecules enable the detection of specific analytes.
• Diagnostics: Use in vitro diagnostic assays as fluorescent labels or contrast agents.
• Photodynamic Therapy: Functioning as photosensitizers or energy donors in therapeutic applications.
• Lighting and Displays: Application in solid-state lighting, display technologies, and anti-counterfeiting features due to their unique optical properties.
• Solar Cells: Potential use in solar energy conversion devices to enhance light harvesting.